Your body makes too many red blood cells – that’s the challenge. But with the right treatment plan, you can manage it, prevent complications, and live a full life.

HISTORY / ORIGIN

Polycythemia vera (PV) was first described as a distinct disease in 1892 by Vaquez, and later recognized as "a new clinical entity" by the famous physician William Osler in 1903. Early treatments were experimental and sometimes risky. In 1918, doctors first used phenylhydrazine to lower red blood cell counts, but it often caused jaundice and other side effects. By the 1940s, radioactive phosphorus (³²P) became a treatment option – until researchers discovered it could lead to acute leukemia. The Polycythemia Vera Study Group, formed in 1967, helped establish more reliable diagnostic criteria and safer treatment approaches. Today, treatment has evolved dramatically, with targeted therapies that work smarter, not harder.

TYPES / CLASSIFICATION OF POLYCYTHEMIA VERA

PV is classified as a myeloproliferative neoplasm (MPN) – a type of blood cancer where the bone marrow produces too many blood cells. It's divided into primary PV (caused by a genetic mutation in the bone marrow) and secondary polycythemia (caused by external factors like low oxygen or tumors). Clinically, PV has two phases according to WHO 2022: the chronic phase (overproduction of red blood cells) and potential progression to myelofibrosis or acute leukemia. About 95% of patients have a JAK2 V617F mutation, while another 5% have JAK2 exon 12 mutations. Patients are also risk-stratified – low-risk (under 60, no history of clots) or high-risk (over 60 or prior thrombosis) – which guides treatment decisions.

MATERIALS / KEY FEATURES – The Tools of Treatment

What does PV treatment actually involve? The approach is multi‑layered:

Phlebotomy – The oldest and most common treatment. Blood is drawn from a vein (like donating blood) to reduce blood volume and excess red cells. The goal is to keep hematocrit below 45%.

Low‑dose Aspirin – Given daily to reduce the risk of blood clots. It also helps relieve burning pain in hands and feet.

Cytoreductive Medications – Drugs that lower blood cell production: Hydroxyurea (first‑line for high‑risk patients), Interferon alfa‑2b, Ropeginterferon alfa‑2b (a newer interferon with fewer doses), and Ruxolitinib (second‑line for those who don't respond to hydroxyurea).

Emerging Targeted Therapies – Research is exploring hepcidin agonists (like rusfertide, which reduces phlebotomy needs), MDM2 inhibitors, and HDAC inhibitors. These aim to correct the underlying disease, not just manage symptoms.

BENEFITS / WHY CHOOSE A STRUCTURED TREATMENT PLAN

✅ Reduces life‑threatening clots – Proper treatment dramatically lowers the risk of stroke, heart attack, and other thrombotic events.

✅ Manages uncomfortable symptoms – Itching (aquagenic pruritus), fatigue, and burning pain in hands and feet can be controlled.

✅ Prevents disease progression – Treatment helps delay or reduce the risk of progression to myelofibrosis or acute leukemia.

✅ Improves quality of life – Patients report less fatigue, better concentration, and more energy with effective management.

✅ Personalized approach – Treatment is tailored to your risk level, symptoms, and how you respond – no one‑size‑fits‑all.

CARE TIPS / LIVING WELL WITH PV

Stick to your phlebotomy schedule – Consistency is key to keeping hematocrit below 45%.

Take low‑dose aspirin daily – Unless your doctor advises otherwise, it's a simple but powerful way to prevent clots.

Stay active – Gentle exercise like walking improves blood flow and lowers clot risk.

Avoid tobacco and high altitudes – Smoking narrows blood vessels; low oxygen at high altitudes can worsen symptoms.

Manage itching – Bathe in cool water, use gentle cleansers, and pat skin dry. Some patients find SSRIs (antidepressants) help with severe itching.

Know your risk status – If you're over 60 or have had a clot, you likely need cytoreductive therapy in addition to phlebotomy and aspirin.

Stay informed – New targeted therapies are emerging. Ask your hematologist about clinical trials or newer options like ropeginterferon or rusfertide.

ENGAGEMENT QUESTION

💬 Have you or a loved one been diagnosed with polycythemia vera? What has been the most helpful part of your treatment journey – or what questions do you still have about managing PV? Share below.